ACTIVTRADES
ActivTrades , one of the world’s leading online Forex Brokers, has won the Le Fonti Forex Broker of the Year Award for the second year running.
This press release features multimedia. View the full release here: http://www.businesswire.com/news/home/20171120005576/en/
A UK-regulated firm with offices in Europe and the Middle East, ActivTrades was selected as the winner by the editorial staff of over 120 journalists at Le Fonti, the international and independent media company and research centre.
Le Fonti credited the broker for “aiming to maximise its clients’ trading through a unique mix of superior value proposition, diverse product offering and stellar customer service ”. Le Fonti’s judges added that ActivTrades offers “some of the tightest spreads in the industry” and a “wide range of professional webinars ”.
ActivTrades specialises in providing industry-leading trading services in Forex and Contracts for Difference. As part of the company’s ongoing commitment to protect its global customer base, ActivTrades doubled its client insurance in September to £1 million, at no additional cost to the customer. This upgraded protection provides further assurances to clients with significantly larger investments.
Ricardo Evangelista , International Desk Manager at ActivTrades, said, “Our corporate values centre on the needs of our clients and it is hugely satisfying to have our efforts recognised for the second year running .”
“In times of rapid industry changes, we pride ourselves on going the extra mile for our clients. Our global customer base of over 50,000 is increasing year-on-year and in the third quarter of 2017 we recorded nearly 20,000 active traders. This is a testament to our ability to meet the market’s expectations as well as our ongoing commitment to expand and add value to our services .”
A highly anticipated celebration uniting the world’s leading corporate stars, the Le Fonti Awards recognises industry leaders in fields such as finance, banking, business and insurance.
ABOUT ACTIVTRADES
ActivTrades is a leading independent broker providing online trading services in Forex, Contracts for Difference (CFDs) and Spread Betting, operating since 2001. From its headquarters in London and its offices in Milan, Sofia and Dubai, ActivTrades serves an expansive global clientele who, over the years, have come to value its continuous innovation, excellent trading environment and effective risk management.
ActivTrades’ award-winning customer service is available 24 hours a day, Sunday evening through to Friday, and assists clients in 14 languages via phone, email and live chat.
A number of globally recognised awards have confirmed ActivTrades’ high standards over the years in areas like customer service, client protection and trading execution. The firm was also included in the Sunday Times Profit Track 100 list in 2017 for its large profit growth.
All leveraged products carry a high degree of risk to your capital and are not suitable for all investors.
ActivTrades PLC is authorised and regulated by the Financial Conduct Authority, registration number 434413.
The ActivTrades Excess of FSCS Insurance is subject to the Terms and Conditions of the policy wording; eligibility to the Financial Services Compensation Scheme depends on the nature and status of the claim.
View source version on businesswire.com: http://www.businesswire.com/news/home/20171120005576/en/
Contact:
ActivTrades
PRESS CONTACT
RACHEL SAM, +44 (0)
207 6500 500
rsam@activtrades.com
or
LAURA
SALVAGE
lauras@pha-media.com
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
MRM Health Raises €55 Million Series B to Advance Best-in-Class Microbiome-Based Biotherapeutic Product Pipeline4.9.2025 07:00:00 CEST | Press release
Funding to support Phase 2b trial with MRM Health’s lead program MH002 in ulcerative colitis and advance two additional programs to IND approval Strategic partnership with Biocodex in biotherapeutics development and manufacturing adds significant non-dilutive funding in addition to the Series B financing Investment fuels expansion of proprietary CORAL® platform and pipeline MRM Health NV, a clinical-stage biopharmaceutical company pioneering microbiome-based therapeutics for inflammatory diseases and immune-oncology, today announced the successful closing of a €55 million (US$64 million) Series B financing round. The round was led by French pharmaceutical group Biocodex and included strong participation from German-based ATHOS, as well as new investor BNP Paribas Fortis Private Equity and existing investors SFPIM, Ackermans & van Haaren (AvH), OMX Europe Venture Fund (OMX), Qbic II and VIB. Validation of Leadership Position in Microbiome-Based Therapeutics Proceeds will enable MRM Heal
Abbove Unveils “Mia”: Opening a New Chapter in Digital Wealth Planning in Europe4.9.2025 06:00:00 CEST | Press release
Artificial Intelligence at the service of wealth advisors and their clients Abbove, the European platform for collaborative and family-centered wealth planning, announces today the launch of Mia, its new artificial intelligence agent. Used by more than 1,100 advisors and deployed to over 37,000 families across Europe, Abbove takes a major step forward in its mission to reimagine the wealth advisory experience in the digital age. Designed to enhance the capabilities of wealth advisors, family officers, and financial experts, Mia acts as an intelligent co-pilot. It simplifies the reading and analysis of complex estate documents, automatically extracts key information, and assists users in the understanding, enrichment, and structuring of wealth data. “The launch of Mia opens an entirely new functional AI vertical on our platform, unlocking near-infinite possibilities for future development. It’s a key milestone that brings us closer to our ambition of becoming the leading pan-European we
Biocytogen Enters into Agreement with Merck, KGaA, Darmstadt, Germany to Advance Antibody-Conjugated Lipid-Based Delivery Solutions4.9.2025 02:00:00 CEST | Press release
Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (Biocytogen, HKEX: 02315), a global biotechnology company that drives the research and development of novel antibody-based drugs with innovative technologies and Merck KGaA, Darmstadt, Germany, a leading science and technology company, have entered into an evaluation and option agreement to advance the development of antibody-conjugated lipid-based delivery solutions for nucleic acid payloads, such as antibody-conjugated lipid nanoparticle (LNP). This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250903434045/en/ Under the terms of the agreement, Biocytogen will provide proprietary, fully human antibodies derived from its RenMice® platform for evaluation in Merck KGaA, Darmstadt, Germany’s antibody-conjugated LNP services. Merck KGaA, Darmstadt, Germany has been granted an exclusive option to acquire rights to selected antibody assets in return for fees and royalties on sales and su
OpZira, Inc. Launches to Advance Ophthalmic Diagnostics with Innovative Medical Device Portfolio3.9.2025 19:23:00 CEST | Press release
OpZira™, Inc., a forward-thinking ophthalmic medical device company founded on a legacy of research excellence, today announced its official formation. OpZira is dedicated to delivering innovative technologies that enhance the detection and monitoring of ocular disease, empowering clinicians with advanced diagnostic tools. OpZira’s creation follows Alcon’s acquisition of LumiThera (https://www.alcon.com/media-release/alcon-completes-acquisition-lumithera/) and its innovative Valeda® Light Delivery System, the first and only FDA-authorized treatment for dry age-related macular degeneration (AMD). As part of the transaction, LumiThera’s diagnostic product lines were spun off to LumiThera shareholders, leading to the establishment of OpZira, Inc. OpZira’s product portfolio includes: AdaptDx Pro® – A wearable dark adaptometer that leverages AI to ensure a consistent patient experience. Impaired dark adaptation speed, a key early indicator of rod-mediated dysfunction, is often among the fir
BTG Bioliquids and NanosTech Partner to Deliver End-to-End Advanced Biofuels Solution3.9.2025 18:19:00 CEST | Press release
BTG Bioliquids BV (BTL), a Netherlands-based leader in fast pyrolysis technology, and NanosTech Technology & Innovations Ltd. (NanosTech), a Canada-based catalyst development and manufacturing company, have signed a Memorandum of Understanding (MOU) to deliver a fully integrated solution to produce advanced, drop-in biofuels. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250903698730/en/ The partnership combines BTL’s proven fast pyrolysis technology, which converts sustainable biomass into bio-oil, with NanosTech’s proprietary Aquaprocessing (AQP) platform, which upgrades even the most challenging bio-oils into refinery-ready feedstocks to produce fuels such as sustainable aviation fuel (SAF), renewable diesel, and marine fuels. The two companies are now actively collaborating to determine the location in Canada and Europe for the new 500-barrel-per-day modular biorefinery system. This system can be deployed near the feeds
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom